Scarica l'app Stockscreener
30.98
2.27%
-0.72
Pre-mercato:
30.66
-0.32
-1.03%
Precedente Chiudi:
$31.70
Aprire:
$31.28
Volume 24 ore:
1.52M
Relative Volume:
1.04
Capitalizzazione di mercato:
$3.73B
Reddito:
$10.12M
Utile/perdita netta:
$-280.49M
Rapporto P/E:
-10.72
EPS:
-2.89
Flusso di cassa netto:
$-188.51M
1 W Prestazione:
+1.31%
1M Prestazione:
-3.67%
6M Prestazione:
-28.00%
1 anno Prestazione:
+14.49%
Intervallo 1D:
$30.15
$31.79
Intervallo di 1 settimana:
$30.00
$32.09
Portata 52W:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Nome
Avidity Biosciences Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta RNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
30.98 | 3.69B | 10.12M | -280.49M | -188.51M | -2.89 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces hurdles - Investing.com Nigeria
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
(RNA) On The My Stocks Page - news.stocktradersdaily.com
Avidity Biosciences Expands Team with $2.2M Stock Package: 16 New Hires Signal Growth - Stock Titan
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Avidity Biosciences Target of Unusually Large Options Trading (NASDAQ:RNA) - Defense World
Stifel Financial Corp Cuts Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for RNA - Defense World
FY2025 EPS Estimates for RNA Lowered by Cantor Fitzgerald - Defense World
When (RNA) Moves Investors should Listen - news.stocktradersdaily.com
Transcript : Avidity Biosciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
Avidity Biosciences Reports Q1 2025 Earnings - TipRanks
Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $68.00 by Analysts at HC Wainwright - Defense World
Avidity Biosciences to Participate in Upcoming Investor Conference - Kilgore News Herald
Avidity Biosciences (RNA) Target Price Lowered by HC Wainwright & Co. | RNA Stock News - GuruFocus
Avidity Biosciences Announces Upcoming Presentations at 2023 Myo - GuruFocus
Avidity Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Avidity Biosciences’ (RNA) Buy Rating Reiterated at Chardan Capital - Defense World
Avidity Biosciences (RNA) Receives Buy Rating from Chardan Capital | RNA Stock News - GuruFocus
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - BioSpace
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
12 Analysts Assess Avidity Biosciences: What You Need To Know - Benzinga
RNA Therapeutics Pioneer Avidity Biosciences Takes Stage at Major Bank of America Healthcare Conference - Stock Titan
(RNA) Investment Report - news.stocktradersdaily.com
Avidity Biosciences chief program officer sells $190k in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief program officer sells $190k in stock - Investing.com Australia
Avidity Biosciences appoints Deloitte as new auditor By Investing.com - Investing.com Canada
Avidity Biosciences appoints Deloitte as new auditor - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus
Federated Hermes Inc. Decreases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt
Avidity’s del-desiran for DM1 named orphan drug in Japan - Muscular Dystrophy News
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga
Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider
Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus
Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com
Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India
Japan grants Avidity's DM1 drug Orphan status - Investing.com
Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
Avidity Biosciences chief program officer sells shares worth $206,799 - MSN
Avidity Biosciences Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Avidity Biosciences Inc Azioni (RNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | Chief Program Officer |
May 01 '25 |
Sale |
32.40 |
5,875 |
190,324 |
50,554 |
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):